Результаты поиска

Emerging Immunotherapy and Antibody-Derived Therapeutics for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Review.

Background: In the last decade, a surge of advancements in and approvals of immunotherapies has revolutionized the treatment of non-small-cell lung cancer (NSCLC). Even as an increasing number of immune checkpoint inhibitors and antibody-drug conjugates gained FDA approval for the remarkable response and durable remission they imparted to some patients, persistent challenges of primary and acquired resistance, imperfect predictive biomarkers, and toxicity remain. Methods: This review identifies and summarizes the most significant emerging clinical data being reported for immunotherapies in NSC

Совпадение в полном тексте источника
… In total, 33% of evaluable patients had a best ORR of SD [ 120 ]. 8.4. [225Ac]Ac-AKY-1189 [225Ac]Ac-AKY-1189 is a radiolabeled antibody engineered to deliver actinium-225 to nectin-4-expressing tumor cells. …

Динамическая стратификация риска в мягкой миеломе: интеграция эволюционирующих биомаркеров с моделью 2/20/20.

Множественная миелома (SMM) является разнородным прекурсором с изменяющимся риском продвижения к миеломе (MM). Нынешние модели рисков основаны на базовых характеристиках, что ограничивает точность прогнозов. Мы стремились определить эволюционирующие факторы риска и интегрировать их в модель 2/20/20 для улучшения стратификации рисков. Мы проанализировали 323 пациента МРМ, диагностированных в соответствии с критериями ММРГ 2014 года в Центре им. Мемориала Слоана Кеттеринга (2002 - 2019 годы). В течение первого года, следующего за диагностикой, была проведена оценка измерений сериала М-протеина и

Совпадение в полном тексте источника
… S.G. reports personal fees and advisory role (scientific advisory board) from Actinium, Celgene, Bristol Myers Squibb, Sanofi, Amgen, Pfizer, GlaxoSmithKline, JAZZ, Janssen, Omeros, Takeda, and Kite. …

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT.

Individual comorbidities have distinct contributions to nonrelapse mortality (NRM) following allogeneic hematopoietic cell transplantation (allo-HCT). We studied the impact of comorbidities individually and in combination in a single-center cohort of 573 adult patients who underwent CD34-selected allo-HCT following myeloablative conditioning. Pulmonary disease, moderate to severe hepatic comorbidity, cardiac disease of any type, and renal dysfunction were associated with increased NRM in multivariable Cox regression models. A Simplified Comorbidity Index (SCI) composed of the 4 comorbidities p

Совпадение в полном тексте источника
… B.G. has received research funding from Actinium. R.J.O. has received consulting fees, research funding, and royalties from Atara Biotherapeutics. I.P. has received research funding from Merck and serves on the Data Safety and Monitoring Board (uncompensated) for ExcellThera. …

МСМ-ММРГ 2025 Консенсусная геномная установка предсказывает результаты с помощью четырехструнных режимов, основанных на дратумумабе, для NDMM.

Международное общество миеломы (ММО) и Международная рабочая группа по миеломе (МРГ) недавно опубликовали новый консенсусный геномический комплект (КОГ) для определения недавно диагностированного множества миеломы (НДММ) с целью обеспечения последовательности в отчетности о клинических испытаниях и для использования при разработке клинических испытаний по обогащению с уделением особого внимания подклассу ЛР. Определение HR является первым, включающим мутации TP53, и предусматривает совместное использование переносов иммуноглобулина Н с хромосомой. 1 Отклонения. С учетом ограниченного объема да

Совпадение в полном тексте источника
… S.G. reports personal fees from, and an advisory role (scientific advisory board) with, Actinium, Celgene, BMS, Sanofi, Amgen, Pfizer, GSK, Jazz, Janssen, Omeros, Takeda, and Kite. …

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.

Graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract is the main cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Ann Arbor (AA) scores derived from serum biomarkers at onset of GVHD quantify GI crypt damage; AA2/3 scores correlate with resistance to treatment and higher NRM. We conducted a multicenter, phase 2 study using natalizumab, a humanized monoclonal antibody that blocks T-cell trafficking to the GI tract through the α4 subunit of α4β7 integrin, combined with corticosteroids as primary treatment for patients with new onset AA2/3 GV

Совпадение в полном тексте источника
… -B.C. received consulting fees from Magenta, Moderna, Equilium, Celularity, Incyte, and Actinium. A.E. is on the advisory board for Kadmon. …

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions.

TP53 aberrations constitute the highest risk subset of myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The International Consensus Classification questions the blast threshold between MDS and AML. In this study, we assess the distinction between MDS and AML for 76 patients with TP53 aberrations. We observed no significant differences between MDS and AML regarding TP53 genomics. Median overall survival (OS) was 223 days for the entire group, but prognostic discrimination within subgroups showed the most inferior OS (46 days) for AML with multihit allelic state plus TP53 varian

Совпадение в полном тексте источника
… JC served on advisory boards for Jazz Pharmaceuticals, Bristol Myters Squibb, MERIT CRO, Pfizer, and Amgen; served as a Data Safety Monitoring Board Member with ICON‐AlloVir and ICON‐Prolacta; owns stock in Actinium Pharmaceuticals, Bluebird Bio/2Seventy, Cellectar Sciences, Dynavax Technologies, aTyr …

Maintenance therapy for AML after allogeneic HCT.

Allogeneic hematopoietic cell transplant (allo-HCT) for eligible patients with acute myeloid leukemia (AML) in first complete remission is a central treatment paradigm to achieve durable remission. However, disease relapse after allo-HCT remains a significant concern and generally portends a poor prognosis. There is significant interest regarding the role for maintenance therapy after allo-HCT for patients with high risk of relapse, regardless of the presence of measurable residual disease. While there are currently no therapies approved for maintenance therapy for AML after allo-HCT, there ar

Совпадение в полном тексте источника
… Conflict of interest YBC has served as a consultant for Novartis, Incyte, Jasper, Celularity, Equilium, Actinium, Daiichi and Abbvie. …

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors.

Neuroendocrine neoplasms make up a heterogeneous group of tumors with inter-patient and intra-patient variabilities. Molecular imaging can help to identify and characterize neuroendocrine tumors (NETs). Furthermore, imaging and treatment with novel theranostics agents offers a new, tailored approach to managing NETs. Recent advances in the management of NETs aim to enhance the effectiveness of targeted treatment with either modifications of known substances or the development of new substances with better targeting features. There have been several attempts to increase the detectability of NET

Совпадение в полном тексте источника
… Radionuclide | Emitted Particle | Half-Life | Utilization Carbon-11 | beta blus | 20 min | Imaging Cobalt-55 | beta plus | 17.5 h | Imaging Copper-64 | beta plus beta minus | 12.7 h | Imaging Therapy Gallium-68 | beta plus | 68 min | Imaging Fluorine-18 | beta plus | 120 min | Imaging Actinium-225 | …

Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?

E-selectin, a cytoadhesive glycoprotein, is expressed on venular endothelial cells and mediates leukocyte localization to inflamed endothelium, the first step in inflammatory cell extravasation into tissue. Constitutive marrow endothelial E-selectin expression also supports bone marrow hematopoiesis via NF-κB-mediated signaling. Correspondingly, E-selectin interaction with E-selectin ligand (sialyl Lewisx) on acute myeloid leukemia (AML) cells leads to chemotherapy resistance in vivo. Uproleselan (GMI-1271) is a carbohydrate analog of sialyl Lewisx that blocks E-selectin binding. A Phase 2 tri

Совпадение в полном тексте источника
… Lazarus: Consultancy for Actinium Pharmaceuticals, CSL Behring, GlycoMimetics Inc., Jazz Pharmaceuticals, Partner Therapeutics, Pluristem Therapeutics Inc., and Seattle Genetics. Equity position in Partner Therapeutics. Speakers’ bureau for AstraZeneca and Bristol-Myers Squibb. …

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.

Lenalidomide is an effective component of induction and maintenance therapy for multiple myeloma, though with a risk of secondary malignancies, including acute lymphoblastic leukemia (ALL). In contrast to therapy-related myeloid neoplasia, lenalidomide-associated lymphoblastic neoplasia remains poorly characterized. We conducted a dual institution retrospective study of 32 ALL cases that arose after lenalidomide maintenance (all B-lineage, 31/32 BCR::ABL-negative). B-cell ALL (B-ALL) was diagnosed at median 54 months (range, 5-119) after first exposure to lenalidomide and after median 42 month

Совпадение в полном тексте источника
… Conflict-of-interest disclosure: M.B.G. received research support from Actinium Pharmaceuticals and Amgen; is on the advisory board of and received research support from Sanofi; and is a consultant for Allogene and Novartis. W.X. received research support from Stemline Therapeutics. …

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.

Solid cancers are the most common types of cancers diagnosed globally and comprise a large number of deaths each year. The main challenge currently in drug development for tumors raised from solid organs is to find more selective compounds, which exploit specific molecular targets. In this work, the small molecule drugs registered by the Food and Drug Administration (FDA) for solid cancers treatment between 2011 and 2022 were identified and analyzed by investigating a type of therapy they are used for, as well as their structures and mechanisms of action. On average, 4 new small molecule agent

Translational Advances in Oncogene and Tumor-Suppressor Gene Research.

Cancer, characterized by the uncontrolled proliferation of cells, is one of the leading causes of death globally, with approximately one in five people developing the disease in their lifetime. While many driver genes were identified decades ago, and most cancers can be classified based on morphology and progression, there is still a significant gap in knowledge about genetic aberrations and nuclear DNA damage. The study of two critical groups of genes-tumor suppressors, which inhibit proliferation and promote apoptosis, and oncogenes, which regulate proliferation and survival-can help to unde

Совпадение в полном тексте источника
… Recent studies have focused on optimizing the combination of targeted radiation and immunotherapy, particularly in treatments that use alpha (radium-223 and actinium-225) and beta radionuclides (90y-ibritumomab tiuxetan), which have shown cytotoxic effects in treating leukemia, prostate cancer, and non-Hodgkin …

Astatine-211 based radionuclide therapy: Current clinical trial landscape.

Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.

Совпадение в полном тексте источника
… This is comparable to other alpha emitters such as thorium-227 ( 227 Th), radium-223 ( 223 Ra), lead-212 ( 212 Pb), bismuth-212 ( 212 Bi), and actinium-225 ( 225 Ac), all of which have a long decay series and may suffer from recoil problems. …

Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.

Despite advances in acute myeloid leukemia (AML) treatment, significant unmet medical needs remain. Surrogate end points for overall survival can accelerate the approval of novel therapies. Measurable residual disease (MRD) is a promising surrogate end point candidate, providing a sensitive and quantitative assessment of disease burden. Numerous studies have demonstrated that negative MRD status-across diverse methodologies, assessment timepoints and thresholds, patient subgroups, and clinical settings-independently predicts improved survival. Although MRD can inform therapeutic decisions at t

Совпадение в полном тексте источника
… Roboz reports grants/contracts from Cellectis and Janssen; and personal/consulting fees from AbbVie, Actinium Pharmaceuticals, Agios Pharmaceuticals Inc., Amgen, Amphivena, Argenyx, Array BioPharma, Astellas Pharma, Astex, AstraZeneca, Bayer, Bluebird Bio, BMS, Caribou Biosciences Inc., Celgene Corporation …

Breaking Boundaries: Immunotherapy for Myeloid Malignancies.

Immunotherapy has revolutionized the treatment of myeloid oncologic diseases, particularly for patients resistant to chemotherapy or ineligible for allogeneic stem cell transplantation due to age or fitness constraints. As our understanding of the immunopathogenesis of myeloid malignancies expands, so too do the treatment options available to patients. Immunotherapy in myeloid malignancies, however, faces numerous challenges due to the dynamic nature of the disease, immune dysregulation, and the development of immune evasion mechanisms. This review outlines the progress made in the field of im

Совпадение в полном тексте источника
… Lintuzumab-Ac225 (Actimab-A) is an antibody-radionuclide conjugate (ARC) that combines the alpha emitter actinium-225 with the anti-CD33 monoclonal antibody lintuzumab. …

Radionuclide-labelled nanoparticles for cancer combination therapy: a review.

Radionuclide therapy (RT) is widely used to advanced local cancers. However, its therapeutic efficacy is limited to the radiation resistance of cancer cells. Combination therapy aims to circumvent tumor resistance, and the combination of RT with photothermal therapy (PTT), photodynamic therapy (PDT), chemotherapy (CMT), and immunotherapy has shown promising treatment outcomes. Nanotechnology holds promise in advancing combination therapy by integrating multiple therapies on a nanostructure platform. This is due to the increased surface area, passive/active targeting capabilities, high payload

Совпадение в полном тексте источника
… Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev. 2008;60(12):1371–82. 36. Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, Lückerath K. …

Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment.

Multiple myeloma is characterized by a wide clinical heterogeneity due to an intricate network of interactions between bone marrow-resident clonal plasma cells and the microenvironment. Over the last years, dramatic improvement in the understanding of these pathways led to the introduction of novel drugs with immune-mediated mechanisms of action. Some of these compounds, such as the anti-cd38 daratumumab and isatuximab, the anti-slamf-7 elotuzumab, and the antibody-drug conjugate belantamab-mafodotin, have been tested in large clinical trials and have now fully entered the real-life management

Совпадение в полном тексте источника
… CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma. Oncoimmunology. 2021;10:2000699. doi: 10.1080/2162402X.2021.2000699. 107. …

Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies.

Small cell lung cancer (SCLC) remains one of the most aggressive malignancies, characterized by rapid proliferation, early metastatic dissemination, and poor long-term survival despite initial sensitivity to therapy. SCLC shares several biologic and therapeutic principles with hematologic malignancies, including lineage state dependence, adaptive resistance through non-genetic plasticity, and emerging susceptibility to antigen-directed immune therapies. Reframing SCLC through this lens provides a conceptual framework for understanding treatment failure and identifying new therapeutic strategie

Совпадение в полном тексте источника
… Radiopharmaceutical Approaches Radioligand | ABD147 | Actinium-225 | Phase I | NCT06736418 V. …

Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice.

BackgroundGlioblastoma (GB), the most aggressive brain cancer, remains a critical clinical challenge due to its resistance to conventional treatments. Here, we introduce a locoregional targeted-α-therapy (TAT) with the rat monoclonal antibody 9E7.4 targeting murine syndecan-1 (SDC1) coupled to the α-emitter radionuclide astatine-211 (211At-9E7.4).MethodsWe orthotopically transplanted 50,000 GL261 cells of murine GB into the right striatum of syngeneic female C57BL/6JRj mice using stereotaxis. After MRI validation of tumour presence at day 11, TAT was injected at the same coordinates. Biodistri

Совпадение в полном тексте источника
… clinical trials and pilot studies have demonstrated the feasibility and low toxicity of intracranial administration of targeted-α-therapies (TATs) in patients, such as tenascin-targeted monoclonal antibodies (mAb) labelled with 211 At, 16 and substance P labelled with bismuth-213 ( 213 Bi) 17 , 18 or with actinium …

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation.

Innovative strategies to re-establish the immune-mediated destruction of malignant cells is paramount to the success of anti-cancer therapy. Accumulating evidence suggests that radiotherapy and select chemotherapeutic drugs and small molecule inhibitors induce immunogenic cell stress on tumors that results in improved immune recognition and targeting of the malignant cells. Through immunogenic cell death, which entails the release of antigens and danger signals, and immunogenic modulation, wherein the phenotype of stressed cells is altered to become more susceptible to immune attack, radiother

Совпадение в полном тексте источника
… Table 3 Clinical trials investigating the combination of small molecule inhibitors with immune checkpoint blockade. 225Ac-J591: alpha-emitter actinium-225 conjugated to the anti-PSMA antibody J591; NDMM: newly diagnosed multiple myeloma; NTE: not transplant eligible; SBRT: stereotactic body radiotherapy …